{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:46Z","timestamp":1793978866056,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2025RC1056"],"award-info":[{"award-number":["2025RC1056"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119226","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:46:22Z","timestamp":1787388382000},"page":"119226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of a novel 10-hydroxy-12-methyl-substituted evodiamine derivative with anti-hepatocellular carcinoma activity through multi-pathway modulation involving suppression of PKA\/AKT signaling cascades and moderate Topo I inhibition"],"prefix":"10.1016","volume":"319","author":[{"given":"Yan","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjue","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3670-124X","authenticated-orcid":false,"given":"Linsheng","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4134-1779","authenticated-orcid":false,"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119226_bib1","first-page":"47","article-title":"Cancer incidence and mortality in China","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.ejmech.2026.119226_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119226_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1667793","article-title":"First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials","volume":"16","author":"Lin","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119226_bib4","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119226_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119226_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.22721","article-title":"Toxicity profiles of systemic therapies for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"5","author":"Griffiths","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejmech.2026.119226_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jjco\/hyx180","article-title":"Chemotherapy for hepatocellular carcinoma: current status and future perspectives","volume":"48","author":"Ikeda","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119226_bib8","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/cancers16081582","article-title":"Hepatocellular carcinoma: current drug therapeutic status, advances and challenges","volume":"16","author":"Zheng","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119226_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106652","article-title":"Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I","volume":"139","author":"Zhang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib10","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3892\/etm.2021.10762","article-title":"Research progress on evodiamine, a bioactive alkaloid of Evodiae fructus: focus on its anti-cancer activity and bioavailability","volume":"22","author":"Luo","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejmech.2026.119226_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0378-4347(95)00090-6","article-title":"High-performance liquid chromatographic determination of evodiamine in rat plasma: application to pharmacokinetic studies","volume":"668","author":"Jeng","year":"1995","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"10.1016\/j.ejmech.2026.119226_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113544","article-title":"Water-soluble derivatives of evodiamine: discovery of evodiamine-10-phosphate as an orally active antitumor lead compound","volume":"220","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116595","article-title":"Design, synthesis and bioactivity evaluation of novel N-phenyl-substituted evodiamine derivatives as potent anti-tumor agents","volume":"55","author":"Hao","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/jm8008663","article-title":"Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS\/MS validation","volume":"52","author":"Trunzer","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.phymed.2012.02.003","article-title":"Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells","volume":"19","author":"Pan","year":"2012","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.119226_bib16","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1021\/acs.jmedchem.9b01626","article-title":"Scaffold hopping of natural product evodiamine: discovery of a novel antitumor scaffold with excellent potency against Colon cancer","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3389\/fphar.2018.00434","article-title":"Evodiamine, a novel NOTCH3 methylation stimulator, significantly suppresses lung carcinogenesis in vitro and in vivo","volume":"9","author":"Su","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119226_bib18","doi-asserted-by":"crossref","first-page":"17346","DOI":"10.1021\/acs.jmedchem.1c01411","article-title":"Discovery of novel polycyclic heterocyclic derivatives from evodiamine for the potential treatment of triple-negative breast cancer","volume":"64","author":"Xu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114530","article-title":"Design, synthesis and bioactivity evaluation of favorable evodiamine derivative scaffold for developing cancer therapy","volume":"239","author":"Liang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113960","article-title":"Design, synthesis and bioactivity evaluation of novel evodiamine derivatives with excellent potency against gastric cancer","volume":"228","author":"Liang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105154","article-title":"Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma","volume":"114","author":"Fan","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105981","article-title":"Discovery of evodiamine derivatives as potential lead antifungal agents for the treatment of superficial fungal infections","volume":"127","author":"Liang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116807","article-title":"Identification of a novel 10-hydroxyevodiamine prodrug as a potent topoisomerase inhibitor with improved aqueous solubility for treatment of hepatocellular carcinoma","volume":"279","author":"Wei","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115366","article-title":"N(14)-substituted evodiamine derivatives as dual topoisomerase 1\/tubulin-Inhibiting anti-gastrointestinal tumor agents","volume":"255","author":"Deng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115031","article-title":"Natural product evodiamine-inspired medicinal chemistry: anticancer activity, structural optimization and structure-activity relationship","volume":"247","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108937","article-title":"N(14)-phenyl-substituted evodiamine derivatives for the treatment of superficial fungal infections by inhibiting xanthine dehydrogenase","volume":"165","author":"Peng","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib27","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1039\/C9CC00434C","article-title":"A concise synthesis and biological study of evodiamine and its analogues","volume":"55","author":"Deng","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.119226_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/ejoc.202500508","article-title":"Synthetic strategies to access fluorinated azoles","volume":"28","author":"Abd El\u2010Gaber","year":"2025","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib29","doi-asserted-by":"crossref","first-page":"13830","DOI":"10.1039\/D6RA01711H","article-title":"Fluorine-containing FDA-approved small-molecule drugs in 2025: significance, synthetic insights, and therapeutic applications","volume":"16","author":"Mishra","year":"2026","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119226_bib30","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jfluchem.2006.06.015","article-title":"Syntheses of 7-fluoro- and 6,7-difluoroserotonin and 7-fluoro- and 6,7-difluoromelatonin","volume":"127","author":"Heredia-Moya","year":"2006","journal-title":"J. Fluor. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116500","article-title":"Discovery of novel small molecules targeting the USP21\/JAK2\/STAT3 axis for the treatment of triple-negative breast cancer","volume":"273","author":"Long","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119226_bib32","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.cell.2025.12.049","article-title":"Hallmarks of cancer-then and now, and beyond","volume":"189","author":"Hanahan","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119226_bib33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119226_bib34","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1099320","article-title":"The pathophysiology of mitochondrial cell death","volume":"305","author":"Green","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119226_bib35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119226_bib36","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1007\/s00204-021-03162-5","article-title":"Topoisomerase poisoning by the flavonoid nevadensin triggers DNA damage and apoptosis in human colon carcinoma HT29 cells","volume":"95","author":"M\u00fcller","year":"2021","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119226_bib37","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/cells8121511","article-title":"Targeting cyclic AMP signalling in hepatocellular carcinoma","volume":"8","author":"Massimi","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119226_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-024-01524-x","article-title":"cAMP-PKA\/EPAC signaling and cancer: the interplay in tumor microenvironment","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:02:23Z","timestamp":1793977343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":38,"alternative-id":["S0223523426006719"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119226","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel 10-hydroxy-12-methyl-substituted evodiamine derivative with anti-hepatocellular carcinoma activity through multi-pathway modulation involving suppression of PKA\/AKT signaling cascades and moderate Topo I inhibition","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119226"}}